These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2360919)

  • 21. Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
    Walldius G; Carlson LA; Erikson U; Olsson AG; Johansson J; Mölgaard J; Nilsson S; Stenport G; Kaijser L; Lassvik C
    Am J Cardiol; 1988 Jul; 62(3):37B-43B. PubMed ID: 3293415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
    Cortese C; Marenah CB; Miller NE; Lewis B
    Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probucol protects low-density lipoproteins from in vitro and in vivo oxidation.
    Bittolo-Bon G; Cazzolato G; Avogaro P
    Pharmacol Res; 1994; 29(4):337-44. PubMed ID: 7971685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats.
    Shankar R; Sallis JD; Stanton H; Thomson R
    Atherosclerosis; 1989 Aug; 78(2-3):91-7. PubMed ID: 2783208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of cholestyramine and probucol in the treatment of familial hypercholesterolaemia.
    Jones DB; Simpson HC; Slaughter P; Lousley S; Carter RD; Cobbe SM; Mann JI
    Atherosclerosis; 1984 Oct; 53(1):1-7. PubMed ID: 6388586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probucol prevents lipid storage in macrophages.
    Yamamoto A; Takaichi S; Hara H; Nishikawa O; Yokoyama S; Yamamura T; Yamaguchi T
    Atherosclerosis; 1986 Dec; 62(3):209-17. PubMed ID: 3801087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
    Steinberg D; Parthasarathy S; Carew TE
    Am J Cardiol; 1988 Jul; 62(3):6B-12B. PubMed ID: 3394654
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
    Walldius G; Erikson U; Olsson AG; Bergstrand L; Hådell K; Johansson J; Kaijser L; Lassvik C; Mölgaard J; Nilsson S
    Am J Cardiol; 1994 Nov; 74(9):875-83. PubMed ID: 7977117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of probucol on the composition and in vitro catabolism of LDL in type IIa hypercholesterolemia.
    Baudet MF; Esteva O; Dachet C; Jacotot B
    Atherosclerosis; 1986 Oct; 62(1):65-71. PubMed ID: 3778575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of probucol on the in vivo plasma clearance of human low density lipoproteins in rabbits and on the expression of lipoprotein receptors in vitro.
    Trezzi E; Roma P; Bernini F; Fumagalli R; Catapano AL
    Atherosclerosis; 1984 Sep; 52(3):309-16. PubMed ID: 6093829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies.
    Hoffman R; Brook GJ; Aviram M
    Atherosclerosis; 1992 Mar; 93(1-2):105-13. PubMed ID: 1596293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of probucol on low-density lipoprotein catabolism in guinea pigs.
    Hidaka K; Takada Y; Matsunaga A; Sasaki J; Arakawa K
    Artery; 1992; 19(3):162-76. PubMed ID: 1637257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of probucol on lipoprotein protein kinetics.
    Nestel PJ
    Artery; 1982; 10(2):95-8. PubMed ID: 7092582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Probucol protects lipoprotein (a) against oxidative modification.
    Naruszewicz M; Selinger E; Dufour R; Davignon J
    Metabolism; 1992 Nov; 41(11):1225-8. PubMed ID: 1435295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia.
    Dachet C; Jacotot B; Buxtorf JC
    Atherosclerosis; 1985 Dec; 58(1-3):261-8. PubMed ID: 4091882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits.
    Mao SJ; Yates MT; Rechtin AE; Jackson RL; Van Sickle WA
    J Med Chem; 1991 Jan; 34(1):298-302. PubMed ID: 1992130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of atherosclerotic progression in Watanabe rabbits by probucol.
    Kita T; Nagano Y; Yokode M; Ishii K; Kume N; Narumiya S; Kawai C
    Am J Cardiol; 1988 Jul; 62(3):13B-19B. PubMed ID: 3394648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic effects of probucol and cholestyramine to lower serum cholesterol.
    Boyden TW; Totman L
    J Clin Pharmacol; 1981 Jan; 21(1):48-51. PubMed ID: 7217343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of probucol on the physical properties of low-density lipoproteins oxidized by copper.
    McLean LR; Hagaman KA
    Biochemistry; 1989 Jan; 28(1):321-7. PubMed ID: 2706256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of probucol on cholesterol and lipoprotein metabolism in man.
    Kesäniemi YA; Grundy SM
    J Lipid Res; 1984 Aug; 25(8):780-90. PubMed ID: 6491523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.